Table 2: Important epitopes of HCV recognized by T cells and B cells.

Ref.AntigenEpitopesFunctional properties
(aa sequence, restriction molecules)

CD8 epitopes

Cooper et al. [58]E1306–315 (CSIYPGHITG, Patr- A 0402); 366–375 (GNWAKVLVVL, Patr- C 0601/ C 0602)cytotoxic epitopes identified in recovered champanzees
E2621–629 (TINYTIFKI, Patr- B 2001); 651–665 (RCDLEDRDRSELSPL, Patr- A 0601)
P7781–791 (KWVPGAVYTFY, Patr- A 0601)
NS2997–1008 (INGLPVSARRGR, Patr- A 0402)
NS31629–1637 (GAVQNEITL, Patr- B 1701)
NS5A2055–2065 (MWSGTFPINAY, Patr- A 0601)

Dazert et al.  [57]NS5B2841–2849 (ARMILMTHF, HLA-B27)IFN- 𝛾 secreting and protective epitope

core41–49 (GPRLGVRAT, HLA-B7); 88–96 (NEGCGWMGW, HLA-B44); 111–119 (DPRRRSRNL, HLA-B7)
E1207–214 (CPNSSIVY, HLA-B35); 322–330 (MMMNWSPTT)
E2541–551 (NTRPPLGNWFG, HLA-B57); 610–619 (YRLWHYPCTI, HLA-Cw7)
NS2831–840 (LSPYYKRYIS, HLA-A25); 941–960 (LGALTGTYVYNHLTPLRDWA); 957–964 (RDWAHNGL, HLA-B37)
Lauer et al. [61]NS31070–1089 (ATCINGVCWTVYHGAGTRTI); 1073–1081 (CINGVCWTV, HLA-A2); 1175–1183 HAVGLFRAA, HLA-A68); 1359–1367 (HPNIEEVAL, HLA-B35); 1395–1403 (HSKKKCDEL, HLA-B8); 1406–1415 (KLVALGINAV, HLA-A2); 1435–1443 (ATDALMTGY, HLA-A1); 1610–1627 (CLIRLKPTLHGPTPLLYR)IFN- 𝛾 secreting epitopes identified in recovered individuals
NS41695–1702 (IPDREVLY, HLA-B35); 1745–1754 (VIAPAVQTNW, HLA-A24); 1751–1770 (VFTGLTHIDAHFLSQTKQSG); 1758–1766 (ETFWAKHMW, HLA-A25); 1771–1790 (GIQYLAGLSTLPGNPAIASL); 1801–1809 (LTTSQTLLF; HLA-B57); 1966–1976 (SECCTPCSGSW, HLA-B37); 1987–1995 (VLDSFKTWL, HLA-A2)
NS52162–2170 (EPEPDVAVL, HLA-B35); 2225–2233 (ELIEANLLW, HLA-A25); 2461–2480 (TSRSACQRQKKVTFDRLQVL); 2594–2602 (ALYDVVTKL, HLA-A2); 2629–2637 (KSKKTPMGF, HLA-B57); 2819–2828 (TARHTPVNSW, HLA-A25); 2912–2921 (LGVPPLRAWR, HLA-B57)

Wedemeyer et al. [60]core35–44 (YLLPRRGPRL, HLA-A2); 132–140 (DLMGYIPLV, HLA-A2)cytotoxic and IFN- 𝛾 secreting epitopes identified in chronic & recovered individuals
NS31073–1081 (CVNGVCWTV, HLA-A2); 1406–1415 (KLVALGINAV, HLA-A2)

Urbani et al. [62]NS31073–1081 (CVNGVCWTV, HLA-A2); 1406–1415 (KLVALGINAV, HLA-A2)Differential expression of CD127 on IFN- 𝛾 secreting C D 8 + 𝑇 cells

CD4 epitopes 

Day et al. [67]NS31248–1262 (GYKVLVLNPSVAATL, HLA- D R B 1 0401); 1579–1597 (SGENLPYLVAYQATVCARA, HLA- D R B 1 0401) C C R 7 + C D 4 5 R A C D 2 7 + tetramer-positive T cells identified in recovered individuals
NS41770–1790 (SGIQYLAGLSTLPGNPAIASL, HLA- D R B 1 0401)

CD4 epitopes

Lasarte et al. [68]core99–112 (SPRGSRPSWGPTDP, HLA-DR); 146–159 (GAARALAHGVRVLE, HLA-DR)Epitopes recognized by IL-2 secreting Th cells in IFN- 𝛼 treatment responders

Schulze zur Wiesch et al. [66]NS31209–1219 (VFTDNSSPPVV, HLA- D R B 3 0201); 1251–1260 (VLVLNPSVAA, HLA- D R B 1 0101/0401/1104 & D R B 3 0101); 1542–1550 (YMNTPGLPV; HLA- D R B 1 0701); 1587–1598 (VAYQATVCARAQ; HLA- D R B 1 1001) Broad specificity to NS3/4/5 proteins identified by proliferation and IFN- 𝛾 secretion in recovered individuals
NS41775–1785 (LAGLSTLPGNP, HLA- D R B 1 0401/0404/0407/1104); 1913–1922 (VQWMNRLIAF, HLA- D R B 1 1104); 1915–1924 (WMNRLIAFAS, HLA- D R B 1 1001)
NS52273–2286 (EILRKSRRFAQALP, HLA- D R B 1 1104); 2423–2436 (SYSWTGALVTPCAA; HLA- D R B 1 0701); 2577–2588 (ARLIVFPDLGVR, HLA- D R B 1 0404/0407); 2944–2954 (YLFNWAVRTKL, HLA- D R B 1 1104)

Antibody epitopes

Law et al. [72]E2396-424/436–447/523–540 (conformational epitope)Conserved cross-genotype, neutralizing antibody epitope

Meunier et al. [70]E1313–327 (ITGHRMAWDMMMNWS)Conserved cross-genotype, neutralizing antibody epitope

Perotti et al. [71]E2412–423/528–535 (conformational epitope)Conserved cross-genotype, neutralizing antibody epitope 

Zhang et al. [43]E2412–426 (QLINTNGSWHINSTA)Conserved cross-genotype, neutralizing antibody epitope 
Unconserved interfering antibody epitope
E2434–446